Clin2
NCT06970951Possibly a fitNot yet recruiting

Cell therapy study for hard-to-treat autoimmune diseases

Systemic Lupus ErythematosusRheumatoid ArthritisDry SyndromeIdiopathic Inflammatory MyopathiesSystemic Sclerosis

Treatments studied

Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.

This trial tests a new cell therapy called UTAA91 for people with autoimmune diseases that have not responded to standard treatments. It aims to see if this treatment can help control the disease.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
15 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have an autoimmune disease (like rheumatoid arthritis, lupus, or others) that hasn't gotten better with standard treatments or has no good treatment options.
  • Your doctor expects you to live at least 3 more months.
  • Your liver, kidneys, heart, and lungs are working well enough.
  • You have not had CAR-T therapy or other gene-modified cell therapy before.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06379646Recruiting
YTS109 cell therapy for autoimmune disease

This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.

Shanghai, Shanghai Municipality
NCT07246096Recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.

Shanghai
NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases

This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.

Nanjing, Jiangsu
NCT07236801Recruiting· Phase 1
Cell therapy for hard-to-treat autoimmune diseases

This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.

Xuzhou, Jiangsu
NCT07236762Recruiting· Phase 1
YTS109 cell therapy for severe autoimmune diseases

This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.

Bengbu
NCT07212322Not yet recruiting
CD19 UCAR-T cells for autoimmune diseases

This trial tests a new cell therapy, CD19 UCAR-T cells, to see if it can help people with certain autoimmune diseases like lupus or scleroderma that haven't improved with standard treatments. It aims to reset the immune system by targeting and removing faulty B cells.

Tianjin, Tianjin Municipality

Hear when a new Systemic Lupus Erythematosus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.